126 related articles for article (PubMed ID: 32063480)
1. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes.
Cloyd JM; Ejaz A; Shen C; Dillhoff M; Williams TM; Noonan A; Pawlik TM; Tsung A
HPB (Oxford); 2020 Nov; 22(11):1569-1576. PubMed ID: 32063480
[TBL] [Abstract][Full Text] [Related]
2. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
3. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Cloyd JM; Wang H; Egger ME; Tzeng CD; Prakash LR; Maitra A; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Overman MJ; Koay EJ; Das P; Herman JM; Kim MP; Vauthey JN; Aloia TA; Fleming JB; Lee JE; Katz MHG
JAMA Surg; 2017 Nov; 152(11):1048-1056. PubMed ID: 28700784
[TBL] [Abstract][Full Text] [Related]
4. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
Blair AB; Yin LD; Pu N; Yu J; Groot VP; Rozich NS; Javed AA; Zheng L; Cameron JL; Burkhart RA; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2021 Jul; 274(1):162-169. PubMed ID: 32304375
[TBL] [Abstract][Full Text] [Related]
5. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.
Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J
Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
7. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
[TBL] [Abstract][Full Text] [Related]
8. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.
Lee AJ; Simoneau E; Chiang YJ; Lee JE; Kim MP; Aloia TA; Vauthey JN; Katz MH; Tzeng CD
HPB (Oxford); 2019 Sep; 21(9):1203-1210. PubMed ID: 30799277
[TBL] [Abstract][Full Text] [Related]
9. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy.
Habib JR; Kinny-Köster B; Bou-Samra P; Alsaad R; Sereni E; Javed AA; Ding D; Cameron JL; Lafaro KJ; Burns WR; He J; Yu J; Wolfgang CL; Burkhart RA
Ann Surg; 2023 Jan; 277(1):151-158. PubMed ID: 33843794
[TBL] [Abstract][Full Text] [Related]
10. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study.
Gantois D; Guilbaud T; Scemama U; Girard E; Picaud O; Lefevre M; Elgani M; Hamidou Z; Moutardier V; Balandraud P; Chirica M; Barbier L; Fuks D; Birnbaum DJ
Langenbecks Arch Surg; 2022 Feb; 407(1):153-165. PubMed ID: 34373941
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
15. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I.
Vega EA; Kutlu OC; Salehi O; James D; Alarcon SV; Herrick B; Krishnan S; Kozyreva O; Conrad C
J Gastrointest Surg; 2020 Oct; 24(10):2409-2415. PubMed ID: 32394126
[TBL] [Abstract][Full Text] [Related]
17. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.
Brown ZJ; Labiner HE; Shen C; Ejaz A; Pawlik TM; Cloyd JM
J Surg Oncol; 2022 Feb; 125(2):185-193. PubMed ID: 34599756
[TBL] [Abstract][Full Text] [Related]
18. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.
Das R; McGrath K; Seiser N; Smith K; Uttam S; Brand RE; Fasanella KE; Khalid A; Chennat JS; Sarkaria S; Singh H; Slivka A; Zeh HJ; Zureikat AH; Hogg ME; Lee KK; Paniccia A; Ongchin MC; Pingpank JF; Boone BA; Dasyam AK; Bahary N; Gorantla VC; Rhee JC; Thomas R; Ellsworth S; Landau MS; Ohori NP; Henn P; Shyu S; Theisen BK; Singhi AD
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):886-897. PubMed ID: 33278573
[TBL] [Abstract][Full Text] [Related]
19. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing.
Oppliger FA; Prakash LR; Newhook TE; Chiang YJ; Ikoma N; Maxwell JE; Kim MP; Vauthey JN; Lee JE; Katz MH; Tzeng CD
Surg Oncol; 2022 Mar; 40():101673. PubMed ID: 34894620
[TBL] [Abstract][Full Text] [Related]
20. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]